Caplacizumab for congenital thrombotic thrombocytopenic purpura

Aaron Boothby; Marshall Mazepa

doi:10.1002/ajh.26693

Caplacizumab for congenital thrombotic thrombocytopenic purpura

Aaron Boothby, Marshall Mazepa

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Caplacizumab rapidly increased platelet count which likely shorted the hospital stay and reduced plasma transfusion requirement.

Original language	English (US)
Pages (from-to)	E420-E421
Journal	American Journal of Hematology
Volume	97
Issue number	11
DOIs	https://doi.org/10.1002/ajh.26693
State	Published - Nov 2022

Keywords

ADAMTS13 Protein
Blood Component Transfusion
Humans
Plasma
Plasma Exchange
Purpura, Thrombotic Thrombocytopenic/drug therapy
Single-Domain Antibodies
von Willebrand Factor

PubMed: MeSH publication types

Letter

Publisher link

10.1002/ajh.26693

Find It

Find It at U of M Libraries

Cite this

@article{6ab6dfdd04114584999ff2344931a4f6,

title = "Caplacizumab for congenital thrombotic thrombocytopenic purpura",

abstract = "Caplacizumab rapidly increased platelet count which likely shorted the hospital stay and reduced plasma transfusion requirement.",

keywords = "ADAMTS13 Protein, Blood Component Transfusion, Humans, Plasma, Plasma Exchange, Purpura, Thrombotic Thrombocytopenic/drug therapy, Single-Domain Antibodies, von Willebrand Factor",

author = "Aaron Boothby and Marshall Mazepa",

year = "2022",

month = nov,

doi = "10.1002/ajh.26693",

language = "English (US)",

volume = "97",

pages = "E420--E421",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "11",

}

TY - JOUR

T1 - Caplacizumab for congenital thrombotic thrombocytopenic purpura

AU - Boothby, Aaron

AU - Mazepa, Marshall

PY - 2022/11

Y1 - 2022/11

N2 - Caplacizumab rapidly increased platelet count which likely shorted the hospital stay and reduced plasma transfusion requirement.

AB - Caplacizumab rapidly increased platelet count which likely shorted the hospital stay and reduced plasma transfusion requirement.

KW - ADAMTS13 Protein

KW - Blood Component Transfusion

KW - Humans

KW - Plasma

KW - Plasma Exchange

KW - Purpura, Thrombotic Thrombocytopenic/drug therapy

KW - Single-Domain Antibodies

KW - von Willebrand Factor

UR - http://www.scopus.com/inward/record.url?scp=85137565210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137565210&partnerID=8YFLogxK

U2 - 10.1002/ajh.26693

DO - 10.1002/ajh.26693

M3 - Article

C2 - 36054034

AN - SCOPUS:85137565210

SN - 0361-8609

VL - 97

SP - E420-E421

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 11

ER -

Caplacizumab for congenital thrombotic thrombocytopenic purpura

Abstract

Keywords

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this